(Q43111232)

14 November 2017

title

Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan (English)

1 reference

Langerhans cell histiocytosis specific to childhood

14 November 2017

main subject

1 reference

4

Hirokazu Kanegane

1 reference

14 November 2017

Toshihiko Imamura

1

1 reference

14 November 2017

Takashi Sato

2

1 reference

14 November 2017

Yoko Shiota

3

1 reference

14 November 2017

Kazuko Kudo

5

1 reference

14 November 2017

Shinichirou Nakagawa

6

1 reference

14 November 2017

Hisaya Nakadate

7

1 reference

14 November 2017

Hisamichi Tauchi

8

1 reference

14 November 2017

Junji Kamizono

9

1 reference

14 November 2017

Akira Morimoto

10

1 reference

14 November 2017

publication date

2 April 2010

1 reference

International Journal of Hematology

14 November 2017

published in

1 reference

14 November 2017

volume

91

1 reference

14 November 2017

issue

4

1 reference

14 November 2017

page(s)

646-651

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-010-0558-0

14 November 2017

exact match

0 references

cites work

Report of the Histiocyte Society workshop on "Central nervous system (CNS) disease in Langerhans cell histiocytosis (LCH)"

1 reference

12 December 2020

The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society

1 reference

12 December 2020

Atypical cellular disorders

1 reference

12 December 2020

Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells

1 reference

12 December 2020

Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine

1 reference

12 December 2020

2-Chlorodeoxyadenosine to treat refractory histiocytosis X.

1 reference

12 December 2020

Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction

1 reference

12 December 2020

Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine

1 reference

12 December 2020

Treatment of cerebral Langerhans cell histiocytosis

1 reference

12 December 2020

Histiocytosis syndromes in children. Writing Group of the Histiocyte Society

1 reference

12 December 2020

Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine.

1 reference

12 December 2020

Cladribine for the treatment of indolent non-Hodgkin's lymphomas

1 reference

12 December 2020

2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis

1 reference

12 December 2020

Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems.

1 reference

12 December 2020

2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients

1 reference

12 December 2020

Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan.

1 reference

12 December 2020

Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study

1 reference

12 December 2020

The role of BMT in childhood histiocytoses

1 reference

12 December 2020

Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature

1 reference

12 December 2020

10.1007/S12185-010-0558-0

Identifiers

DOI

1 reference

14 November 2017

1 reference